Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis

BACKGROUND: Tocilizumab is a humanized monoclonal anti-interleukin-6 (IL-6) receptor antibody and has been approved in Japan for the treatment of Castleman’s disease, rheumatoid arthritis (RA), and systemic juvenile idiopathic arthritis. Conjunctivitis and dry eye are known ocular adverse effects, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Tomohito, Minakuchi, Shinya, Mochizuki, Manabu, Takeuchi, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891663/
https://www.ncbi.nlm.nih.gov/pubmed/24531503
http://dx.doi.org/10.2147/OPTH.S54929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891663/
https://www.ncbi.nlm.nih.gov/pubmed/24531503
http://dx.doi.org/10.2147/OPTH.S54929

Ejemplares similares